FDA Approves Supplemental NDA for ZIAC by Teva
The FDA has approved a supplemental NDA for ZIAC, which contains bisoprolol fumarate and hydrochlorothiazide.
Published: July 29, 2026
Updated: July 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Hypertension
Company: Teva
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Teva
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of the supplemental NDA for ZIAC is significant as it strengthens Teva's position in the competitive hypertension market. Portfolio teams must evaluate the potential impact on market dynamics and prepare for competitive responses.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for any upcoming market launch details and competitor responses in the hypertension segment.
Related companies & assets
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.